These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 7912819

  • 21. Acute and subacute CNS effects of milacemide in elderly people: double-blind, placebo-controlled quantitative EEG and psychometric investigations.
    Saletu B, Grünberger J, Linzmayer L.
    Arch Gerontol Geriatr; 1986 Oct; 5(3):165-81. PubMed ID: 3541816
    [Abstract] [Full Text] [Related]

  • 22. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group.
    Puech A, Fleurot O, Rein W.
    Acta Psychiatr Scand; 1998 Jul; 98(1):65-72. PubMed ID: 9696517
    [Abstract] [Full Text] [Related]

  • 23. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride.
    Paillère-Martinot ML, Lecrubier Y, Martinot JL, Aubin F.
    Am J Psychiatry; 1995 Jan; 152(1):130-4. PubMed ID: 7802104
    [Abstract] [Full Text] [Related]

  • 24. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?
    Blin O.
    Encephale; 2000 Oct; 26 Spec No 1():7-11. PubMed ID: 11294060
    [Abstract] [Full Text] [Related]

  • 25. Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.
    Delcker A, Schoon ML, Oczkowski B, Gaertner HJ.
    Pharmacopsychiatry; 1990 May; 23(3):125-30. PubMed ID: 1973843
    [Abstract] [Full Text] [Related]

  • 26. The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.
    Herrera-Estrella M, Apiquian R, Fresan A, Sanchez-Torres I.
    BMC Psychiatry; 2005 May 03; 5():22. PubMed ID: 15869707
    [Abstract] [Full Text] [Related]

  • 27. [Relation between blood levels and average quantitative EEG and psychometrically assessed pharmacodynamic changes following zotepine].
    Saletu B, Grünberger J, Anderer P, Chwatal K.
    Fortschr Neurol Psychiatr; 1991 Sep 03; 59 Suppl 1():45-55. PubMed ID: 1683340
    [Abstract] [Full Text] [Related]

  • 28. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
    Lin CH, Wang FC, Lin SC, Huang YH, Chen CC, Lane HY.
    Int Clin Psychopharmacol; 2013 Sep 03; 28(5):267-74. PubMed ID: 23778382
    [Abstract] [Full Text] [Related]

  • 29. Comparative pharmacodynamic studies with the novel serotonin uptake-enhancing tianeptine and -inhibiting fluvoxamine utilizing EEG mapping and psychometry.
    Saletu B, Grünberger J, Anderer P, Linzmayer L, Zyhlarz G.
    J Neural Transm (Vienna); 1996 Sep 03; 103(1-2):191-216. PubMed ID: 9026373
    [Abstract] [Full Text] [Related]

  • 30. CEEG mapping in drug-free schizophrenics. Differences from healthy subjects and changes induced by haloperidol treatment.
    Galderisi S, Mucci A, Mignone ML, Maj M, Kemali D.
    Schizophr Res; 1991 Dec 03; 6(1):15-23. PubMed ID: 1786232
    [Abstract] [Full Text] [Related]

  • 31. Early clinical pharmacological trials with a novel partial benzodiazepine agonist/antagonist Ro 17-1812 using pharmaco-EEG and psychometry.
    Saletu B, Grünberger J, Linzmayer L.
    Methods Find Exp Clin Pharmacol; 1986 Jun 03; 8(6):373-89. PubMed ID: 3736281
    [Abstract] [Full Text] [Related]

  • 32. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
    Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S.
    Acta Psychiatr Scand; 2006 Nov 03; 114(5):319-27. PubMed ID: 17022791
    [Abstract] [Full Text] [Related]

  • 33. EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID.
    Saletu B, Anderer P, Fischhof PK, Lorenz H, Barousch R, Böhmer F.
    Biol Psychiatry; 1992 Oct 15; 32(8):668-81. PubMed ID: 1457622
    [Abstract] [Full Text] [Related]

  • 34. [Profile of the action of neuroleptics in deficit schizophrenia].
    Vanelle JM.
    Encephale; 1996 Jun 15; 22 Spec No 2():33-9. PubMed ID: 8767040
    [Abstract] [Full Text] [Related]

  • 35. Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
    Zink M, Knopf U, Henn FA, Thome J.
    Pharmacopsychiatry; 2004 Jan 15; 37(1):26-31. PubMed ID: 14750045
    [Abstract] [Full Text] [Related]

  • 36. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S.
    JAMA Psychiatry; 2015 Jan 15; 72(1):14-21. PubMed ID: 25372935
    [Abstract] [Full Text] [Related]

  • 37. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies.
    Saletu B, Möller HJ, Grünberger J, Deutsch H, Rössner M.
    Neuropsychobiology; 2015 Jan 15; 24(4):173-84. PubMed ID: 2135708
    [Abstract] [Full Text] [Related]

  • 38. Amisulpride--an open clinical study of a new benzamide in schizophrenic patients.
    Mann K, Bartels M, Bauer H, Gaertner HJ.
    Pharmacopsychiatry; 1984 Jul 15; 17(4):111-5. PubMed ID: 6147865
    [Abstract] [Full Text] [Related]

  • 39. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I, Ravanić D, Popović V, Vladejić S, Stanojević A, Stojanović M.
    Psychiatr Danub; 2011 Dec 15; 23(4):384-8. PubMed ID: 22075740
    [Abstract] [Full Text] [Related]

  • 40. Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis.
    Müller MJ, Wetzel H, Benkert O.
    Int Clin Psychopharmacol; 2002 Sep 15; 17(5):249-61. PubMed ID: 12177587
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.